• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CTKB

    Cytek Biosciences Inc.

    Subscribe to $CTKB
    $CTKB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    IPO Year: 2021

    Exchange: NASDAQ

    Recent Analyst Ratings for Cytek Biosciences Inc.

    DatePrice TargetRatingAnalyst
    5/9/2025$4.00Buy → Hold
    TD Cowen
    1/31/2025$7.00 → $4.50Buy → Sell
    Goldman
    12/14/2023$9.00Overweight
    Stephens
    7/19/2023Mkt Perform
    Raymond James
    2/15/2022$27.00 → $18.00Equal-Weight
    Morgan Stanley
    1/6/2022$20.00Overweight
    Piper Sandler
    10/15/2021Outperform
    Cowen
    8/17/2021Outperform
    Cowen
    8/17/2021Equal-Weight
    Morgan Stanley
    8/17/2021$26.00Equal-Weight
    Morgan Stanley
    See more ratings

    Cytek Biosciences Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Mccombe William D. bought $97,300 worth of shares (35,000 units at $2.78), increasing direct ownership by 169% to 55,746 units (SEC Form 4)

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/3/25 5:39:17 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Cytek Biosciences Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Chin Richard

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/20/25 4:31:59 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 3 filed by new insider Chin Richard

      3 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/20/25 4:27:18 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Director Neff Deborah J

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/20/25 4:25:14 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Director Ball Jack

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/20/25 4:20:15 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Director Holder Michael

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/20/25 4:18:01 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Director Imper Vera

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/20/25 4:15:45 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Imper Vera converted options into 15,706 shares (SEC Form 4)

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/9/25 5:11:39 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Hardison Don M converted options into 15,706 shares (SEC Form 4)

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/9/25 5:08:59 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Ball Jack converted options into 15,706 shares, increasing direct ownership by 58% to 42,705 units (SEC Form 4)

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/9/25 5:04:32 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Neff Deborah J converted options into 15,706 shares (SEC Form 4)

      4 - Cytek Biosciences, Inc. (0001831915) (Issuer)

      6/9/25 4:57:14 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Cytek Biosciences Inc. SEC Filings

    See more
    • SEC Form 8-K filed by Cytek Biosciences Inc.

      8-K - Cytek Biosciences, Inc. (0001831915) (Filer)

      6/24/25 4:05:58 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SD filed by Cytek Biosciences Inc.

      SD - Cytek Biosciences, Inc. (0001831915) (Filer)

      5/30/25 4:00:54 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by Cytek Biosciences Inc.

      SCHEDULE 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

      5/15/25 2:07:36 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 10-Q filed by Cytek Biosciences Inc.

      10-Q - Cytek Biosciences, Inc. (0001831915) (Filer)

      5/8/25 5:21:43 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Cytek Biosciences, Inc. (0001831915) (Filer)

      5/8/25 4:11:40 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by Cytek Biosciences Inc.

      SCHEDULE 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

      4/30/25 10:57:47 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Cytek Biosciences Inc.

      DEFA14A - Cytek Biosciences, Inc. (0001831915) (Filer)

      4/28/25 4:20:19 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEF 14A filed by Cytek Biosciences Inc.

      DEF 14A - Cytek Biosciences, Inc. (0001831915) (Filer)

      4/28/25 4:18:46 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form S-8 filed by Cytek Biosciences Inc.

      S-8 - Cytek Biosciences, Inc. (0001831915) (Filer)

      2/28/25 4:45:01 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Cytek Biosciences, Inc. (0001831915) (Filer)

      2/27/25 4:09:05 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Cytek Biosciences Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cytek Biosciences downgraded by TD Cowen with a new price target

      TD Cowen downgraded Cytek Biosciences from Buy to Hold and set a new price target of $4.00

      5/9/25 8:41:00 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences downgraded by Goldman with a new price target

      Goldman downgraded Cytek Biosciences from Buy to Sell and set a new price target of $4.50 from $7.00 previously

      1/31/25 6:59:30 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Stephens initiated coverage on Cytek Biosciences with a new price target

      Stephens initiated coverage of Cytek Biosciences with a rating of Overweight and set a new price target of $9.00

      12/14/23 6:55:41 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Raymond James initiated coverage on Cytek Biosciences

      Raymond James initiated coverage of Cytek Biosciences with a rating of Mkt Perform

      7/19/23 7:28:12 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Morgan Stanley reiterated coverage on Cytek Biosciences with a new price target

      Morgan Stanley reiterated coverage of Cytek Biosciences with a rating of Equal-Weight and set a new price target of $18.00 from $27.00 previously

      2/15/22 9:32:22 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Piper Sandler resumed coverage on Cytek Biosciences with a new price target

      Piper Sandler resumed coverage of Cytek Biosciences with a rating of Overweight and set a new price target of $20.00

      1/6/22 7:20:42 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cowen resumed coverage on Cytek Biosciences

      Cowen resumed coverage of Cytek Biosciences with a rating of Outperform

      10/15/21 7:19:14 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cowen initiated coverage on Cytek Biosciences

      Cowen initiated coverage of Cytek Biosciences with a rating of Outperform

      8/17/21 10:32:12 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Morgan Stanley initiated coverage on Cytek Biosciences

      Morgan Stanley initiated coverage of Cytek Biosciences with a rating of Equal-Weight

      8/17/21 8:34:43 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Morgan Stanley initiated coverage on Cytek Biosciences with a new price target

      Morgan Stanley initiated coverage of Cytek Biosciences with a rating of Equal-Weight and set a new price target of $26.00

      8/17/21 8:08:52 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Cytek Biosciences Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

      IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25

      7/3/25 1:00:00 PM ET
      $CTKB
      $MDXH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care
    • Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer

      FREMONT, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- In a move that underscores its dedication to shaping the future of cell analysis, Cytek Biosciences, Inc. (NASDAQ:CTKB) today announced the launch of the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on its flagship Cytek Aurora system. First launched in 2017 to address the limitations of existing flow cytometry technologies, Cytek's Full Spectrum Profiling™ (FSP®) systems have become the spectral technology of choice for researchers worldwide, with over 2,600 peer-reviewed publications citing its use – more than any other spectral flow cytometer. Building on this groundbreaking success, the new Cytek Aurora E

      5/29/25 5:00:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference

      FREMONT, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL. Cytek management is scheduled to participate in a fireside chat on Wednesday, June 11th at 11:40 a.m. Pacific Time / 2:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: investors.cytekbio.com. About Cytek Biosciences, Inc. Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next

      5/28/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences Reports First Quarter 2025 Financial Results

      FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. First Quarter Highlights Total revenue for the first quarter of 2025 was $41.5 million, representing a 7.6% decrease compared to the first quarter of 2024Expanded to a total installed base of 3,149 Cytek instruments, including the Amnis® and Guava® instruments shipped since the acquisition of the product lines in February 2023, adding 115 units in the first quarter of 2025Commenced operations in Singapore to access low-cost manufacturing, increa

      5/8/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025

      FREMONT, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Continuing its commitment to advancing cell analysis, Cytek Biosciences, Inc. (NASDAQ:CTKB) is showcasing its patented Full Spectrum Profiling™ (FSP®) technology at CYTO 2025 and American Association of Immunologists' (AAI) IMMUNOLOGY2025. Designed to streamline workflows, accelerate discoveries, and enhance efficiency, FSP technology will be the focus of a variety of demonstrations, educational workshops and tutorials at these prominent industry gatherings. Flow cytometry plays a crucial role in both research and clinical studies, and Cytek is at the forefront of making this powerful technology more accessible and scalable. By empowerin

      4/29/25 5:00:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025

      FREMONT, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next generati

      4/24/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

      FREMONT, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2024. Recent Highlights Total revenue was $200.5 million, or $201.3 million on a non-GAAP constant currency basis, for the full year 2024, representing 3.9% and 3.9% increases, respectively, over the full year 2023Expanded total Cytek installed base to 3,034 instruments, with 667 total instruments placed during the full year 2024 Net loss in the year ended December 31, 2024 was $6.0 million compared to net loss of $12.1 million in th

      2/27/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

      FREMONT, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, February 27, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com About Cytek BiosciencesCytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next ge

      2/13/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences to Participate in Upcoming Investor Conferences

      FREMONT, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT Participating on Tuesday, February 11 and Wednesday, February 12, 2025 Raymond James 46th Annual Institutional Investors Conference in Orlando, FLPresentation on Monday, March 3, 2025, at 3:25 p.m. Eastern Time / 12:25 p.m. Pacific Time TD Cowen 45th Annual Health Care Conference in Boston, MAFireside chat on Wednesday, March 5, 2025, at 10:30 a.m. Eastern Time / 7:30 a

      2/5/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences Announces Preliminary Full Year 2024 Revenue Results

      FREMONT, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the full year ended December 31, 2024. Cytek expects its full year revenue for 2024 to be between $200 million and $201 million, representing 4% growth over Cytek's 2023 revenue of $193.0 million. This included a negative foreign exchange impact of approximately $1.0 million. Expected fourth quarter revenue of $57 million to $58 million represents growth of 11% to 13% compared to the third quarter of 2024 and decline of 2% to flat compared to a strong fourth quarter of 2023. The appreciation of the

      1/15/25 8:00:00 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Cytek Biosciences Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change

      IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25

      7/3/25 1:00:00 PM ET
      $CTKB
      $MDXH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care
    • Cytek Announces Resignation of Chief Operating Officer Chris Williams

      FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure. During his tenure, Williams played key roles in the company's growth, spearheading initiatives that improved operational processes and paving the way for Cytek's future success. His leadership has been integral to enhancing the company's ef

      9/12/24 3:20:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek® Biosciences Names William McCombe Chief Financial Officer

      Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook FREMONT, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB) today announced that William (Bill) McCombe has been appointed chief financial officer of the company effective immediately. McCombe brings experience as a public company CFO at both large scale, and smaller, high growth technology companies. He was CFO at Velo3D, a leader in metal 3D printing systems for the aerospace and other industries, CFO at HZO, a leader in delivering protective nano coatings for electronics, and EVP and CFO at Maxar Technologies, a multi-billion-

      3/19/24 8:00:00 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences Appoints Dr. Philippe Busque Senior Vice President of Global Sales & Services

      FREMONT, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the appointment of Philippe Busque, Ph.D. as Senior Vice President of Global Sales & Services. In this newly created position, Dr. Busque will lead an enhanced global sales organization encompassing all customer facing functions worldwide, including sales, service, and technical application support, building on the recently integrated sales team that combines the original Cytek sales force with the Amnis® and Guava® sales force. "Philippe's extensive global sales and marketing experience as an executive at several life science companies, incl

      8/28/23 5:30:00 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences Appoints Todd Garland Chief Commercial Officer

      FREMONT, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the appointment of Todd Garland as Chief Commercial Officer, Cytek Biosciences, Inc. Garland's appointment is effective immediately, reporting directly to Dr. Wenbin Jiang, Chairman and CEO of Cytek Biosciences. "I have long admired Cytek's advanced technology and products, and I am particularly pleased to join the company because I believe Cytek has a real opportunity to become the premier company in the cell analysis industry," commented Garland. Garland's prior professional career spans BD Biosciences, CareFusion and Cardinal

      4/28/22 8:00:00 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Cytek Biosciences Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Cytek Biosciences Inc.

      SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

      11/14/24 4:35:51 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Cytek Biosciences Inc.

      SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

      11/14/24 1:42:15 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Cytek Biosciences Inc.

      SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

      2/22/24 7:07:27 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Cytek Biosciences Inc. (Amendment)

      SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

      2/14/24 4:39:04 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Cytek Biosciences Inc. (Amendment)

      SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

      2/14/24 4:08:58 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Cytek Biosciences Inc. (Amendment)

      SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

      2/14/24 4:07:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Cytek Biosciences Inc.

      SC 13G - Cytek Biosciences, Inc. (0001831915) (Subject)

      2/14/24 3:12:34 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Cytek Biosciences Inc. (Amendment)

      SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

      2/13/24 5:02:40 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Cytek Biosciences Inc. (Amendment)

      SC 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)

      1/23/24 4:13:59 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13D/A filed by Cytek Biosciences Inc. (Amendment)

      SC 13D/A - Cytek Biosciences, Inc. (0001831915) (Subject)

      9/19/23 5:25:11 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Cytek Biosciences Inc. Financials

    Live finance-specific insights

    See more
    • Cytek Biosciences Reports First Quarter 2025 Financial Results

      FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. First Quarter Highlights Total revenue for the first quarter of 2025 was $41.5 million, representing a 7.6% decrease compared to the first quarter of 2024Expanded to a total installed base of 3,149 Cytek instruments, including the Amnis® and Guava® instruments shipped since the acquisition of the product lines in February 2023, adding 115 units in the first quarter of 2025Commenced operations in Singapore to access low-cost manufacturing, increa

      5/8/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025

      FREMONT, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next generati

      4/24/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

      FREMONT, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2024. Recent Highlights Total revenue was $200.5 million, or $201.3 million on a non-GAAP constant currency basis, for the full year 2024, representing 3.9% and 3.9% increases, respectively, over the full year 2023Expanded total Cytek installed base to 3,034 instruments, with 667 total instruments placed during the full year 2024 Net loss in the year ended December 31, 2024 was $6.0 million compared to net loss of $12.1 million in th

      2/27/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

      FREMONT, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, February 27, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com About Cytek BiosciencesCytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next ge

      2/13/25 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences Reports Third Quarter 2024 Financial Results

      FREMONT, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Total revenue for the third quarter of 2024 was $51.5 million, representing a 7% increase over the third quarter of 2023 and a 10% increase over the second quarter of 2024. Year-to-date revenue of $143.0 million at September 30, 2024 was 6% above the same 9 month period in 2023 Launched SpectroPanel™ tool, a proprietary new intelligent algorithm which suggests optimized panels in minutes, expanding the capabilities of the Pane

      11/5/24 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024

      FREMONT, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 5, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com. About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the nex

      10/29/24 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences Reports Second Quarter 2024 Financial Results

      FREMONT, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Total revenue for the second quarter of 2024 was $46.6 million, representing a 4% increase sequentially over the first quarter of 2024 and a 6% decrease over the second quarter of 2023For the first half of 2024, total revenue grew 5% compared to the first half of 2023Launched Enhanced Small Particle (ESP™) detection, an upgrade option for the Cytek Aurora™ and Northern Lights™ systems for the analysis of viruses and other sub-

      8/6/24 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences to Report Second Quarter 2024 Financial Results on August 6, 2024

      FREMONT, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced it will report financial results for the second quarter 2024 after market close on Tuesday, August 6, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com. About Cytek Biosciences, Inc. Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the

      7/30/24 4:05:00 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences Reports First Quarter 2024 Financial Results

      FREMONT, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Total revenue was $44.9 million, representing a 21% increase over the corresponding period of 2023 Organic revenue was $37.3 million, representing an increase of 11% compared to the first quarter of 2023First quarter revenue from the product lines acquired from Luminex Corporation ("Luminex") on February 28, 2023 was $7.6 million Opened a new 50,000-square-foot facility in Wuxi, China to meet growing global demand for cutting-edge

      5/8/24 4:05:53 PM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024

      FREMONT, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced it will report financial results for the first quarter 2024 after market close on Wednesday, May 8th, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com. About Cytek Biosciences, Inc. Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advanci

      4/29/24 9:00:00 AM ET
      $CTKB
      Biotechnology: Laboratory Analytical Instruments
      Industrials